| Broad and potent activity against SARS-like viruses by an engineered human monoclonal antibody CG Rappazzo, LV Tse, CI Kaku, D Wrapp, M Sakharkar, D Huang, ... Science 371 (6531), 823-829, 2021 | 316 | 2021 |
| Prolonged evolution of the human B cell response to SARS-CoV-2 infection M Sakharkar, CG Rappazzo, WF Wieland-Alter, CL Hsieh, D Wrapp, ... Science immunology 6 (56), eabg6916, 2021 | 188 | 2021 |
| Recall of preexisting cross-reactive B cell memory after Omicron BA. 1 breakthrough infection CI Kaku, AJ Bergeron, C Ahlm, J Normark, M Sakharkar, MNE Forsell, ... Science immunology 7 (73), eabq3511, 2022 | 121 | 2022 |
| Broad anti–SARS-CoV-2 antibody immunity induced by heterologous ChAdOx1/mRNA-1273 vaccination CI Kaku, ER Champney, J Normark, M Garcia, CE Johnson, C Ahlm, ... Science 375 (6584), 1041-1047, 2022 | 73 | 2022 |
| A broad and potent neutralization epitope in SARS-related coronaviruses M Yuan, X Zhu, W He, P Zhou, CI Kaku, T Capozzola, CY Zhu, X Yu, H Liu, ... Proceedings of the National Academy of Sciences 119 (29), e2205784119, 2022 | 59 | 2022 |
| Evolution of antibody immunity following Omicron BA. 1 breakthrough infection CI Kaku, TN Starr, P Zhou, HL Dugan, P Khalifé, G Song, ER Champney, ... Nature Communications 14 (1), 2751, 2023 | 56 | 2023 |
| Antibody-mediated protection against symptomatic COVID-19 can be achieved at low serum neutralizing titers P Schmidt, K Narayan, Y Li, CI Kaku, ME Brown, E Champney, ... Science Translational Medicine 15 (688), eadg2783, 2023 | 29 | 2023 |
| Human antibodies to SARS-CoV-2 with a recurring YYDRxG motif retain binding and neutralization to variants of concern including Omicron H Liu, CI Kaku, G Song, M Yuan, R Andrabi, DR Burton, LM Walker, ... Communications Biology 5 (1), 766, 2022 | 14 | 2022 |
| Prolonged evolution of the human B cell response to SARS-CoV-2 infection. Sci Immunol 6: eabg6916 M Sakharkar, CG Rappazzo, WF Wieland-Alter, CL Hsieh, D Wrapp, ... | 14 | 2021 |
| An engineered antibody with broad protective efficacy in murine models of SARS and COVID-19 CG Rappazzo, VT Longping, CI Kaku, D Wrapp, M Sakharkar, D Huang, ... bioRxiv, 2020 | 14 | 2020 |
| Revisiting an IgG Fc loss-of-function experiment: the role of complement in HIV broadly neutralizing antibody b12 activity BS Goldberg, CI Kaku, J Dufloo, T Bruel, O Schwartz, DA Spencer, ... Mbio 12 (5), 10.1128/mbio. 01743-21, 2021 | 8 | 2021 |
| ADG20, a half-life–extended monoclonal antibody in development for the prevention and treatment of COVID-19, demonstrated broad in vitro neutralisation against SARS-CoV-2 variants CI Kaku, P Schmidt, F Engler, Y Li, LM Walker 32nd European Congress of Clinical Microbiology & Infectious Diseases (ECCMID), 2022 | 6 | 2022 |
| A recurring YYDRxG pattern in broadly neutralizing antibodies to a conserved site on SARS-CoV-2, variants of concern, and related viruses H Liu, CI Kaku, G Song, M Yuan, R Andrabi, DR Burton, LM Walker, ... biorxiv, 2021.12. 15.472864, 2021 | 6 | 2021 |
| Evolution of antibody immunity following Omicron BA. 1 breakthrough infection. bioRxiv CI Kaku, TN Starr, P Zhou, HL Dugan, P Khalifé, G Song, ER Champney, ... | 5 | 2022 |
| Evolution of antibody immunity following Omicron BA. 1 breakthrough infection (preprint) CI Kaku, TN Starr, P Zhou, HL Dugan, P Khalife, G Song, ER Champney, ... | 5* | 2022 |
| Prophylactic Administration of the Monoclonal Antibody Adintrevimab Protects against SARS-CoV-2 in Hamster and Non-Human Primate Models of COVID-19 EE Zumbrun, CI Kaku, L Dillinger, SE Zak, AI Kuehne, RR Bakken, ... Antimicrobial Agents and Chemotherapy 67 (1), e01353-22, 2023 | 4 | 2023 |
| Broad anti-SARS-CoV-2 antibody immunity induced by heterologous ChAdOx1/mRNA-1273 prime-boost vaccination CI Kaku, ER Champney, J Normark, CE Johnson, C Ahlm, M Sakharkar, ... medRxiv, 2021.12. 13.21267598, 2021 | 2 | 2021 |
| Recall of pre-existing cross-reactive B cell memory following Omicron breakthrough infection (preprint) CI Kaku, AJ Bergeron, C Ahlm, J Normark, M Sakharkar, MNE Forsell, ... | | 2022 |
| Broad anti-SARS-CoV-2 antibody immunity induced by heterologous ChAdOx1/mRNA-1273 prime-boost vaccination (preprint) C Kaku, E Champney, J Normark, C Johnson, C Ahlm, M Sakharkar, ... | | 2021 |
| An Engineered Antibody with Broad Protective Efficacy in Murine Models of SARS and COVID-19 (preprint) CG Rappazzo, VT Longping, CI Kaku, D Wrapp, M Sakharkar, D Huang, ... | | 2020 |
